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S U M M A R Y
Objectives: To assess the safety and immunogenicity of a meningococcal polysaccharide diphtheria
toxoid conjugate vaccine (MenACYW–D) in a Korean population.
Methods: This was a phase III, blind-observer, controlled study in which participants aged 11–55 years
were randomized (2:1 ratio) to a single dose of MenACYW–D or tetanus/diphtheria/acellular pertussis
(Tdap) vaccine. Outcomes included rates of seroconversion against all serogroups (4-fold increase in
antibody titer from pre-vaccination), geometric mean titers (GMTs) at days 0 and 28 based on a serum
bactericidal assay using baby rabbit complement, rates of seroprotection (titer 1:128) at day 28, and
safety.
Results: A total of 300 participants were enrolled in the study (200 MenACYW–D and 100 Tdap).
Seroconversion rates for serogroups A, C, Y, and W-135 were 77.8%, 88.3%, 74.6%, and 92.4%, respectively,
for the MenACYW–D group and 9.3%, 8.1%, 12.2%, and 8.2%, respectively, for the Tdap group. The
proportions of participants with pre-vaccination titers 1:128 were 57.3%, 12.6%, 51.5%, and 22.2% for
serogroups A, C, Y, and W-135, respectively; post-vaccination rates were 98.5%, 89.4%, 96.0%, and 95.0%
for the MenACYW–D group. A lower proportion of participants reported solicited reactions with
MenACYW–D (46.2%) compared with Tdap (76.8%).
Conclusion: A single dose of MenACYW–D was well tolerated and elicited a robust immune response in
Korean adolescents and adults.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Meningococcal disease is caused by the Gram-negative aerobic
diplococcus Neisseria meningitidis. Meningococci are classiﬁed by
serogroup based on the immunochemistry of the polysaccharide
capsule.1 Invasive meningococcal disease (IMD), such as meningi-
tis and meningococcemia, is most frequently caused by serogroupsciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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IMD is rapidly progressive and associated with high mortality rates
of 7% to 19%.3 Approximately 10% to 20% of patients suffer from
permanent disabilities such as limb loss, deafness, seizures, or
psychomotor retardation.2 Meningococci colonize the nasophar-
ynx of approximately 4.5% to 25% of the normal population.4 The
reported incidence of meningococcal disease varies widely, but
recent outbreaks provide evidence for the continued potential of
the meningococcus to cause global morbidity and mortality.4
Meningococcal meningitis is a notiﬁable disease in the Republic
of Korea (ROK). The annual number of reported cases varied
between 1 and 38 in the years 2001–2014, or approximately
0.01 to 0.08 cases per 100 000 population per year.5 However, the
number of reported cases increased dramatically in 2002 (n = 27)
and 2003 (n = 38). In particular, an outbreak caused by serogroup
W-135 in military recruits in 2011 raised the issue as to whether
military personnel should be vaccinated with a quadrivalent
meningococcal conjugate vaccine (serogroups ACYW).6 No me-
ningococcal vaccine was licensed at that time in the ROK. In
November 2012, the Korean Ministry of Defense introduced a new
vaccine policy, including mandatory meningococcal vaccination
(serogroups ACYW) for all new recruits.
Polysaccharide meningococcal vaccines have been used widely
in high-risk individuals and for the control of outbreaks. These
vaccines elicit a largely T-cell-independent response and are
poorly immunogenic in children, and therefore do not confer long-
lasting immunity. Repeated administration of these vaccines may
result in hyporesponsiveness.7,8 They are unlikely to reduce
nasopharyngeal carriage in the long term, and therefore are
unlikely to induce herd immunity. On the other hand, meningo-
coccal conjugate vaccines induce a largely T-cell-dependent
response, can provide broad, long-lasting primary protection,
and induce immunologic memory, as well as possible herd
protection by reducing carriage. The development and introduc-
tion of meningococcal conjugate vaccines hold great potential for
the control of meningococcal disease.4
The meningococcal (groups A, C, Y, and W-135) polysaccharide
diphtheria toxoid conjugate vaccine (MenACYW–D, Menactra;
Sanoﬁ Pasteur, Swiftwater, Pennsylvania, USA) has been shown to
be safe, immunogenic, and to induce immune memory and provide
durable protection in multiple clinical trials as required by the
World Health Organization.8–12 The purpose of this study was to
assess the safety and immunogenicity of a single dose of
MenACYW–D in a healthy Korean population aged 11 to 55 years.
The primary objective of the study was to demonstrate that the
seroconversion rates were >60% for serogroups A, C, Y, and W-135
after a single dose of MenACYW–D.
2. Materials and methods
2.1. Study design
A phase III, blind-observer, randomized, controlled, single-dose,
multicenter study was conducted in the ROK. Healthy participants
11 to 55 years of age were randomized in a 2:1 ratio to MenACYW–
D and Tdap. All participants received a single dose of vaccine on
day 0 and provided blood samples for immunogenicity assessment
on day 0 (pre-vaccination) and on day 28 (post-vaccination).
Vaccines were administered intramuscularly in the deltoid. Safety
data, including serious adverse events (SAEs), were collected from
day 0 through day 28 (+7 days).
Participants were enrolled by age group (children/adolescents
and adults) and assigned a number for randomization. Scratch-off
randomization lists were generated by an independent statistician
who was not involved in conducting the study; this was done
through randomization by block using programming under SASversion 9.2 and Proc Plan. Investigators, participants, and the study
sponsor were blinded to the treatment arm. Enrollment ensured
that 30% of participants were children and adolescents (11 to
17 years of age) and 40% were adults (18 to 55 years of age).
The primary endpoint was the seroconversion status (deﬁned as
a 4-fold increase in antibody titer compared to the pre-
vaccination level) against meningococcal serogroups A, C, Y, and
W-135 at 28 days after vaccination. Secondary endpoints included
the rates of seroconversion and seroprotection (titer 1:128) at
28 days after vaccination. Seroconversion was deﬁned as a 4-fold
increase in antibody titers from the pre-vaccination level against
meningococcal serogroups A, C, Y, and W-135 at 28 days after
vaccine administration.
Safety outcomes included (1) the occurrence and relationship to
vaccination of any SAEs occurring at any time during the study, (2)
the occurrence of systemic unsolicited adverse events (AEs)
reported within 30 min after vaccination, (3) the occurrence, time
to onset, number of days of occurrence, and intensity of pre-
deﬁned (solicited) injection site reactions and systemic reactions
occurring from day 0 through day 7 after vaccination, and (4) the
occurrence, nature, maximum intensity (for non-SAEs only), and
relationship to vaccination (for systemic AEs only) of unsolicited
(spontaneously reported) AEs within 28 days after vaccination.
Solicited injection site reactions were categorized as grade 1 (no
interference with activity), grade 2 (some interference with
activity), or grade 3 (signiﬁcant; prevents daily activity). Erythema
and swelling were categorized as grade 1 (25 to 50 mm), grade
2 (51 to 100 mm), or grade 3 (>100 mm). Solicited systemic
reactions were graded for fever, headache, malaise, and myalgia.
Fever was categorized as grade 1 (38.0 8C to 38.4 8C), grade 2
(38.5 8C to 38.9 8C), or grade 3 (39.0 8C). Headache, malaise,
and myalgia were categorized as grade 1 (no interference with
activity), grade 2 (some interference with activity), or grade 3
(signiﬁcant; prevents daily activity).
The protocol was approved by the Korea Food and Drug
Administration (KFDA) and by the institutional review board at
each site. The study complied with the Declaration of Helsinki,
International Conference on Harmonization, Good Clinical Practice,
and with local and national regulations and directives. At least one
parent/legal representative for participants aged 11 to 19 years and
all participants aged 20 to 55 years provided written informed
consent. This trial was registered under ClinicalTrials.gov identiﬁer
NCT01642589.
2.2. Participants
Eligible participants were 11 to 55 years of age and had health
insurance coverage. Exclusion criteria included the following:
previous vaccination against meningococcal disease; vaccination
against diphtheria or tetanus in the past 5 years or any previous
vaccination with any other tetanus/diphtheria/acellular pertussis
(Tdap) vaccine; receipt or planned receipt of any vaccine in the
previous 4 weeks or following trial vaccination (except for
inﬂuenza vaccines); receipt of immune globulins, blood, or
blood-derived products in the past 3 months; receipt of oral or
injectable antibiotic therapy within the 72 h prior to the ﬁrst blood
sample collection; congenital or acquired immunodeﬁciency,
immunosuppressive therapy within the previous 6 months, or
long-term corticosteroid use for more than two consecutive weeks
in the previous 3 months; thrombocytopenia, bleeding disorder, or
receipt of anticoagulants in the previous 3 weeks; known
hypersensitivity to any vaccine components; high risk for IMD
or history of conﬁrmed IMD; history of Guillain–Barre´ syndrome;
chronic illness that could interfere with participation in the trial;
pregnancy or lactation; or participation in another clinical trial
within 4 weeks of initiating this trial.
Participants enrolled
N = 300
Allocated to Men-ACYW-D
n = 200
Discontinued study
n = 1
Voluntary withdrawal
not due to an AE
Received vaccine
n = 200
Completed study
n = 199
Discontinued study
n = 1
Voluntary withdrawal
not due to an AE
Completed study
n = 99
FAS: n = 200
PPAS: n = 191
SafAS: n = 200
FAS: n = 100
PPAS: n = 92
SafAS: n = 100
Received vaccine
n = 100
Allocated to Tdap
n = 100
Figure 1. Participant disposition. FAS, full analysis set; SafAS, safety analysis set;
PPAS, per-protocol analysis set; AE, adverse event.
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Each 0.5-ml dose of MenACYW–D contains 4 mg each of
meningococcal A, C, Y, and W-135 polysaccharides conjugated to
approximately 48 mg of diphtheria toxoid protein in sodium
phosphate buffered isotonic sodium chloride solution. Each 0.5-ml
dose of Tdap (Adacel; Sanoﬁ Pasteur Inc., Swiftwater, PA, USA)
contains tetanus toxoid (5 Lf; 20 IU), diphtheria toxoid (2 Lf; 2 IU),
pertussis toxoid (2.5 mg), ﬁlamentous hemagglutinin (5 mg), pertactin
(3 mg), ﬁmbriae types 2 and 3 (5 mg), aluminum phosphate adjuvant
(1.5 mg; 0.33 mg aluminum), and 2-phenoxyethanol (0.6% v/v).
2.4. Serologic evaluations
Functional meningococcal antibody activity against serogroups
A, C, Y, and W-135 antigens contained in MenACYW–D was
measured using a serum bactericidal assay with baby rabbit
complement (SBA-BR). The SBA-BR measures the antibody-mediat-
ed, complement-dependent killing of target bacteria, as described
previously.9,13 The lower limit of quantitation of the SBA-BR was a
titer of 4 (1/dil). Titers 1:8 are considered protective.14Assays were
performed by Global Clinical Immunology at Sanoﬁ Pasteur Inc.
2.5. Statistical analyses
A sample size of 175 evaluable participants in the MenACYW–D
group was estimated using the exact binomial method to provide an
overall power of at least 96% based on the primary analysis and
observed antibody responses from previous trials. A total sample
size of 300 participants (200 MenACYW–D; 100 Tdap) was planned
to accommodate a 12.5% drop-out rate and an allocation ratio of 2:1.
No hypothesis was tested for the primary endpoint. A 95%
conﬁdence interval (CI) was constructed around the point estimates
of the seroconversion rates of the overall population for serogroups
A, C, Y, and W-135.15The primary objective was achieved if the lower
limit of the 95% CI was >60% for the respective serogroups.
Seroprotection and seroconversion rates were calculated with their
95% CIs using the exact binomial method. Geometric mean titers
(GMTs) were calculated with their 95% CIs using the normal
approximation of the log2 titers followed by a back-transformation.
The superiority of MenACYW–D was evaluated in comparison to
Tdap in terms of the seroconversion rate at 28 days after the
vaccination. For each serogroup, the superiority was demonstrated if
the 95% CI of the difference (study vaccine  control vaccine) lay
entirely above 0 (alpha = 2.5%). The 95% CI was calculated based on
the Wilson score method without continuity correction.15 All safety
analyses were descriptive, and 95% CIs of point estimates were
calculated using the normal approximation for quantitative data and
the exact binomial distribution (Clopper–Pearson method) for
proportions.16 No imputation for missing data was performed.
Statistical analyses were performed using SAS version 9.2 software
(SAS Institute, Inc., Cary, NC, USA).
The safety analysis set (SafAS) comprised all participants who
received the study vaccine or control vaccine. The full analysis set
(FAS) consisted of all randomized participants who received the
study vaccine or control vaccine. The per-protocol analysis set
(PPAS) comprised participants who received study vaccine or
control vaccine and complied with all protocol-speciﬁed require-
ments and procedures.
3. Results
3.1. Participants
The study was conducted between July 13, 2012 and January 17,
2013 at eight sites in the ROK. A total of 300 participants wereenrolled and randomized (200 in the MenACYW–D group and
100 in the Tdap group); two participants (one from each group) did
not complete the study because of voluntary withdrawal not due to
an AE (Figure 1). Of the 300 participants, all were included in the
SafAS and FAS and 283 (94.3%) were included in the PPAS. Of the
300 participants, 165 (55.0%) were female. The mean age of the
participants was 24.7 years (standard deviation (SD) 11.0); 148
(49.3%) were adolescents (age 11 to 17 years) and 151 (50.3%) were
adults (age 18 to 55 years). Demographic characteristics were
similar between the two study groups.
3.2. Immunogenicity
The MenACYW–D group demonstrated higher seroconversion
rates to all four serogroups than the Tdap group in the FAS
(Table 1). The lower limit of the 95% CIs of the seroconversion rates
were above 60% for all four serogroups at 28 days after MenACYW–
D administration. The lower limits of the 95% CIs of the differences
in seroconversion rates between MenACYW–D and Tdap for all
four serogroups was >0, demonstrating superiority of MenACYW–
D over Tdap. Similar results were observed for the PPAS. In the
MenACYW–D group, the most marked differences between pre-
vaccination and post-vaccination antibody titers were observed for
serogroups C and W-135 (Table 2). Pre-vaccination seroprotection
rates were similar between the two groups for serogroups A, C, Y,
and W-135 (Table 3). Seroprotection rates for all serogroups
increased at 28 days after vaccination in the MenACYW–D group
(98.5%, 89.4%, 96.0%, and 95.0% for serogroups A, C, Y, and W-135,
respectively), but not in the Tdap group (Table 3).
3.3. Safety and tolerability
No immediate unsolicited AEs were reported. SAEs or AEs
leading to discontinuation were not reported. No safety concerns
were identiﬁed.
Solicited injection site reactions were reported by 33.2% and
72.7% of participants in the MenACYW–D group and Tdap group,
respectively, and solicited systemic reactions were reported by
36.7% and 51.5%, respectively (Table 4). The most common
solicited injection site reaction was pain and the most common
Table 1
Seroconversion rates at day 28 post-vaccination (FAS)a
Serogroup MenACYW–D (n = 200) Tdap (n = 100) Differenceb (95% CI) Superiority of MenACYW–Dc
n/M % (95% CI) n/M % (95% CI)
A 154/198 77.8 (71.3, 83.4) 9/97 9.3 (4.3, 16.9) 68.5 (58.8, 75.3) Yes
C 174/197 88.3 (83.0, 92.5) 8/99 8.1 (3.6, 15.3) 80.2 (71.5, 85.7) Yes
Y 147/197 74.6 (67.9, 80.5) 12/98 12.2 (6.5, 20.4) 62.4 (52.1, 69.9) Yes
W-135 182/197 92.4 (87.8, 95.7) 8/98 8.2 (3.6, 15.5) 84.2 (75.8, 89.2) Yes
FAS, full analysis set; n, number of participants with seroconversion; M, number of participants with data available; CI, conﬁdence interval.
a Seroconversion was deﬁned as antibody titers 4-fold higher than pre-vaccination levels.
b Difference in seroconversion rates between MenACYW–D and Tdap groups.
c Superiority was deﬁned as a lower limit >0 of the 95% CI around the difference in seroconversion rates.
Table 2
Pre-vaccination and post-vaccination GMTRs (FAS)
MenACYW–D (n = 200) Tdap (n = 100)
Serogroup Pre-vaccination
GMT (95% CI)
Post-vaccination
GMT (95% CI)
GMTR (95% CI) Pre-vaccination
GMT (95% CI)
Post-vaccination
GMT (95% CI)
GMTR (95% CI)
A 46.1 (33.7, 63.2) 1121 (949, 1324) 23.8 (16.9, 33.6) 75.6 (48.9, 117) 87.6 (57.1, 135) 1.2 (0.87, 1.5)
C 5.80 (4.50, 7.46) 667 (504, 884) 119 (85.7, 166) 4.63 (3.26, 6.56) 5.64 (3.82, 8.32) 1.2 (0.94, 1.6)
Y 50.1 (37.7, 66.6) 620 (521, 738) 12.3 (9.4, 16.1) 47.2 (31.9, 69.8) 66.8 (45.5, 98.0) 1.4 (1.1, 1.7)
W-135 13.0 (9.83, 17.1) 851 (690, 1050) 64.7 (47.8, 87.5) 11.9 (7.8, 18.1) 14.9 (9.5, 23.4) 1.3 (1.0, 1.6)
GMTR, geometric mean titer ratio (post-vaccination GMT/pre-vaccination GMT); FAS, full analysis set; GMT, geometric mean titer; CI, conﬁdence interval.
Table 3
Seroprotection rates (FAS)a
Serogroup MenACYW–D Tdap
Pre-vaccination n (%) Post-vaccination n (%) Pre-vaccination n (%) Post-vaccination n (%)
A 114 (57.3) 196 (98.5) 64 (64.0) 68 (70.1)
C 25 (12.6) 178 (89.4) 15 (15.0) 16 (16.2)
Y 102 (51.5) 191 (96.0) 48 (48.0) 56 (57.1)
W-135 44 (22.2) 189 (95.0) 25 (25.0) 26 (26.5)
FAS, ﬁnal analysis set.
a Seroprotection was deﬁned as a titer of 1:128.
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were of grade 1 or grade 2 in intensity, occurred primarily between
day 0 and day 3, and resolved spontaneously.
Unsolicited AEs were reported by 8.5% and 9.0% of participants
in the MenACYW–D group and Tdap group, respectively (Table 5).
The most commonly reported unsolicited AEs were upper
respiratory tract infection (1.5%) in the MenACYW–D group and
nasopharyngitis (3.0%) in the Tdap group. Unsolicited adverse
reactions (ARs) were reported by 2.0% and 3.0% of participants in
the MenACYW–D group and the Tdap group, respectively.
4. Discussion
This study demonstrated that the MenACYW–D vaccine was
well tolerated and immunogenic in healthy adolescents and adults
(aged 11 to 55 years) in the ROK. The immune response, as
measured by seroconversion rates for all four serogroups A, C, Y,
and W-135, was higher than 60% of participants (based on 95% CI)
with a single dose of MenACYW–D, and met the primary objective
of the study. Moreover, statistical superiority of MenACYW–D over
Tdap was demonstrated in terms of the proportion of participants
with seroconversion. These results provide sufﬁciently unambigu-
ous data to permit a decision for licensing and public health
recommendations of a meningococcal polysaccharide diphtheria
toxoid conjugate vaccine (MenACYW–D; Menactra).
Meningococcal vaccination is recommended for persons at high
risk of meningococcal disease: persons with functional or
anatomical asplenia, deﬁciencies of either a terminal complementcomponent or properdin, and persons who travel to endemic
countries.8,17 The acquisition of meningococcal infection depends
on the chance of encountering virulent bacteria. New military
recruits have been recognized as a high-risk group, probably
related to crowding of persons from various geographic areas who
might carry diverse meningococcal strains.18
Currently, the overall incidence of meningococcal disease in the
general population is low in the ROK. Meningococcal vaccination
had not been considered in the Korean armed forces until 2011,
when an outbreak of meningococcal disease at an army recruit
training center brought the issue to the public’s attention. The
outbreak led the military authorities to establish a policy of
mandatory meningococcal vaccination for new recruits starting in
2012.6 The outbreak involved four cases of invasive disease,
resulting in one case of mortality. Meningococcal serogroup W-
135 was detected in the serum and cerebrospinal ﬂuid samples
obtained from three patients by real-time PCR.19 In a previous
study to determine the incidence and serogroups of meningococcal
disease in the Korean army from August 2000 to July 2001, a total
of 12 IMD cases were identiﬁed, with an incidence of 2.2 cases per
100 000 population per year. In the 10 patients tested for the
causative serogroups, only serogroups A (one case) and C (three
cases) were identiﬁed.20 Another study on nine isolates from
civilian IMD cases collected in 2002 and 2003 revealed serogroups
Y (seven cases), B (one case), and 29E (one case).21 Therefore, the
use of quadrivalent (A, C, Y, W-135) meningococcal conjugate
vaccine is needed to prevent IMD in the ROK, along with laboratory
surveillance of N. meningitidis throughout the country.
Table 4
Summary of solicited AEs (FAS)
MenACYW–D (n = 200) Tdap (n = 100)
Participants experiencing 1: n/M % (95% CI) n/M % (95% CI)
Solicited injection site reaction 66/199 33.2 (26.7, 40.2) 72/99 72.7 (62.9, 81.2)
Injection site pain 64/199 32.2 (25.7, 39.1) 72/99 72.7 (62.9, 81.2)
Grade 1 50/199 25.1 (19.3, 31.7) 47/99 47.5 (37.3, 57.8)
Grade 2 13/199 6.5 (3.5, 10.9) 23/99 23.2 (15.3, 32.8)
Grade 3 1/199 0 (0.0, 2.8) 2/99 2.0 (0.2, 7.1)
Injection site erythema 5/199 2.5 (0.8, 5.8) 9/99 9.1 (4.2, 16.6)
Grade 1 3/199 1.5 (0.3, 4.3) 8/99 8.1 (3.6, 15.3)
Grade 2 2/199 1.0 (0.1, 3.6) 1/99 1.0 (0.0, 5.5)
Grade 3 0/199 0 (0.0, 1.8) 0/99 0 (0.0, 3.7)
Injection site swelling 3/199 1.5 (0.3, 4.3) 6/99 6.1 (2.3, 12.7)
Grade 1 2/199 1.0 (0.1, 3.6) 6/99 6.1 (2.3, 12.7)
Grade 2 1/199 0.5 (0.0, 2.8) 0/99 0 (0.0, 3.7)
Grade 3 0/199 0 (0.0, 1.8) 0/99 0 (0.0, 3.7)
Solicited systemic reaction 73/199 36.7 (30.0, 43.8) 51/99 51.5 (41.3, 61.7)
Fever 0/199 0 (0.0, 1.8) 3/99 3.0 (0.6, 8.6)
Grade 1 0/199 0 (0.0, 1.8) 2/99 2.0 (0.2, 7.1)
Grade 2 0/199 0 (0.0, 1.8) 1/99 1.0 (0.0, 5.5)
Grade 3 0/199 0 (0.0, 1.8) 0/99 0 (0.0, 3.7)
Headache 37/199 18.6 (13.4, 24.7) 24/99 24.2 (16.2, 33.9)
Grade 1 28/199 14.1 (9.6, 19.7) 17/99 17.2 (10.3, 26.1)
Grade 2 7/199 3.5 (1.4, 7.1) 6/99 6.1 (2.3, 12.7)
Grade 3 2/199 1.0 (0.1, 3.6) 1/99 1.0 (0.0, 5.5)
Malaise 36/199 18.1 (13.0, 24.2) 23/99 23.2 (15.3, 32.8)
Grade 1 29/199 14.6 (10.0, 20.3) 18/99 18.2 (11.1, 27.2)
Grade 2 6/199 3.0 (1.1, 6.4) 4/99 4.0 (1.1, 10.0)
Grade 3 1/199 0.5 (0.0, 2.8) 1/99 1.0 (0.0, 5.5)
Myalgia 51/199 25.6 (19.7, 32.3) 42/99 42.4 (32.5, 52.8)
Grade 1 37/199 18.6 (13.4, 24.7) 25/99 25.3 (17.1, 35.0)
Grade 2 13/199 6.5 (3.5, 10.9) 16/99 16.2 (9.5, 24.9)
Grade 3 1/199 0.5 (0.0, 2.8) 1/99 1.0 (0.0, 5.5)
AE, adverse event; FAS, full analysis set; n, number of participants with event; M, number of participants with data available; CI, conﬁdence interval.
Table 5
Summary of unsolicited AEs and ARs (FAS)
Participants experiencing 1: MenACYW–D (n = 200) Tdap (n = 100)
n % (95% CI) n % (95% CI)
Unsolicited AE 17 8.5 (5.0, 13.3) 9 9.0 (4.2, 16.4)
Unsolicited non-serious AE 17 8.5 (5.0, 13.3) 9 9.0 (4.2, 16.4)
Grade 3 0 0 (0.0, 1.8) 1 1.0 (0.0, 5.4)
Unsolicited non-serious systemic AE 17 8.5 (5.0, 13.3) 6 6.0 (2.2, 12.6)
Grade 3 0 0 (0.0, 1.8) 1 1.0 (0.0, 5.4)
Unsolicited AR 4 2.0 (0.5, 5.0) 3 3.0 (0.6, 8.5)
Unsolicited non-serious AR 4 2.0 (0.5, 5.0) 3 3.0 (0.6, 8.5)
Unsolicited non-serious systemic AR 2 1.0 (0.1, 3.6) 0 0 (0.0, 3.6)
AE, adverse event; AR, adverse reaction; FAS, full analysis set; CI, conﬁdence interval.
D.S. Kim et al. / International Journal of Infectious Diseases 45 (2016) 59–64 63The MenACYW–D vaccine was ﬁrst licensed in the USA in
2005 and has been recommended for adolescents by the Advisory
Committee on Immunization Practices.17 Early estimates reported
80% to 85% effectiveness of MenACWY–D within 3 to 4 years after
vaccination.11 Although coverage has varied substantially by state
since the introduction of the vaccine, the proportion of IMD
attributable to serogroups C, W, and Y has decreased approxi-
mately 50% in persons aged 11 to 19 years compared with the rate
observed during the years 1993–2005.22 MenACYW–D was
introduced in the US military in 2007.
The immunogenicity of MenACYW–D in this study is consistent
with the historical data of a randomized controlled trial of healthy
adolescents in the USA during the early 2000s,9 although the
interpretation of historical comparisons is difﬁcult because of
changes in population exposure and laboratory differences in SBA
procedures. In a recent placebo-controlled study of a single dose of
quadrivalent meningococcal conjugate vaccine (MenACYW-CRM)
conducted in Korean subjects aged 11 to 55 years, the rate of
seroresponse with post-vaccination SBA using a human comple-
ment (hSBA) titer 1:8 against all four serogroups, ranged from79% (serogroup A) to 94–99% (other three serogroups).23 However,
the proportion of participants with a pre-vaccination hSBA titer
1:4 was 88% for serogroup W-135, which was not observed in the
present study measuring the SBA with baby rabbit serum as the
complement source.
In this study, the MenACYW–D vaccine was well tolerated. No
participant reported an immediate unsolicited AE or an SAE. There
were no deaths during the study. The percentage of participants
reporting each type of AE in the MenACYW–D group was lower
than that in the Tdap group. In both groups, most solicited injection
site and systemic reactions were of grade 1 or grade 2 intensity and
were of short duration. In both groups, unsolicited AEs and ARs
were reported in low proportions and were of grade 1 or grade
2 intensity. The only grade 3 unsolicited AE in the Tdap group was
considered as not related to Tdap.
A limitation of this study was the absence of a meningococcal
comparator vaccine. This was because no other meningococcal
vaccine was licensed in the ROK at the beginning of the trial. For
ethical reasons it was preferred to use an active control vaccine
(Tdap) rather than a placebo control.
D.S. Kim et al. / International Journal of Infectious Diseases 45 (2016) 59–6464In conclusion, this study conﬁrmed that a single dose of
MenACYW–D induced an immune response with a seroconversion
rate of >60% of participants for all four serogroups (A, C, Y, and W-
135), and was superior to a single dose of Tdap as measured by
seroconversion rates for all four serogroups. Pre-vaccination titers
for serogroups A and Y were appreciable, suggesting that many
participants had previous exposure to N. meningitidis. MenACYW–
D had a good safety proﬁle. On the basis of current and previous
results, MenACYW–D vaccine has the potential to provide broad
serogroup protection in Korean adolescents and adults.
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